This discussion focuses on the challenges of global drug development and the long-term implications of COVID-19.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
Critical reagents – the key components used in LBA – are central to ensuring the consistency and reliability of the assay and can often slow the progress of LBA due to limited availability. In this panel discussion, we examine the current scope of LBAs, the advantages and limitations including matrix interference, as well as the solutions for overcoming these. Additionally, we explore the platforms currently used and the key factors to consider when choosing a platform. Finally, we will highlight key areas for progression.
In this podcast, we discuss the role of genetic toxicology in drug development.
In this podcast, we discuss delivery modalities for sterile product development of poorly water-soluble drugs, with our special guest: Dr. Manish Mujal, Director of Product Development and CTM Manufacturing at Frontage Laboratories, Inc.